跳至主要内容
临床试验/CTRI/2007/091/000037
CTRI/2007/091/000037已完成2 期

Open label, randomized multicentric clinical trial of Mycobacterium w in combination with Paclitaxel plus Cisplatin versus paclitxel and cisplatin in advanced Non Small Cell Lung Cancer.

Cadila Pharmaceuticals ltd0 个研究点目标入组 221 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
221

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.INFORMED CONSENT OBTAINED & SIGNED:
  • o Ability to understand and the willingness to sign a written informed consent document.
  • 2.DISEASE CHARACTERISTICS:
  • o Histologically or cytologically confirmed Non-Small Cell Lung Cancer, Stage IIIB or IV
  • 3.PATIENT CHARACTERISTICS:
  • -18 completed years and above
  • o Performance status
  • -ECOG 0-1
  • o Life expectancy
  • -At least 24 weeks
  • o Hematopoietic
  • -Absolute neutrophil count >= 1,500/mm3
  • -Platelet count >= 1,00,000/mm3
  • -Hemoglobin >= 9.0 g/dL
  • -AST and ALT <= 2.5 times upper limit of normal (ULN) range of institution (5 times ULN if liver metastasis present).
  • -Bilirubin not greater than 1.5 times ULN range of institution (3 times ULN if liver involvement).
  • - Serum Creatinine less than 1.5 times upper limit of normal (ULN) range of Institutional Lab Range.
  • 4. Negative Pregnancy test for women of child bearing potential prior to entry into the trial.

排除标准

  • 1. Patients who have had cytotoxic chemotherapy or radiotherapy prior to entering the study.
  • 2. Patients with symptomatic brain metastasis
  • 3. History of allergic reactions attributed to paclitaxel, cisplatin or mycobacteria or any of their ingredients.
  • 4. Pregnant women or nursing women
  • 5. Uncontrolled intercurrent illness that would limit compliance with study requirements.
  • 6. HIV positive patients
  • 7. Previous splenectomy

研究者

相似试验

已完成
不适用
Multicentre, open-label randomised clinical trial of efficacy and tolerability of the fixed-dose artesunate/amodiaquine (AS/AQ) combination therapy and amodiaquine (AQ) monotherapy for treatment of uncomplicated falciparum malaria in IndiaMalaria
ISRCTN84408319Drugs for Neglected Diseases initiative (DNDi) (Switzerland)300
进行中(未招募)
1 期
Comparison Of Envarsus® and Advagraf® In adult kidney transplant patientsImmunosuppression in adult de-novo kidney transplantMedDRA version: 18.0Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 100000004865
EUCTR2014-005572-28-FRChiesi Farmaceutici S.p.A.
进行中(未招募)
1 期
An open label, prospective, multicenter trial, on the effect of anti-TNF alpha Chimeric monoclonal antibody (Infliximab, Remicade) on the inflammatory and fibrous lesions in patients with intestinal Crohn's Disease.Crohn's disease
EUCTR2006-004784-58-FRCHRU de Lille25
已完成
3 期
Multicenter, randomized, open-label, clinical study on the agreement of Scintimun® Granulocyte and labeled 99m Tc-White Blood Cells in diagnosing infection/inflammation by immunoscintigraphy in peripheral bone and joints with suspected osteomyelitis.bot- en gewrichtaandoeningenbonemarrow and its surrounding connective tissuecentral osteitis / inflammation of the bone10019815
NL-OMON29943CIS bio International26
进行中(未招募)
不适用
Multicenter, randomized, open-label, clinical study on the agreement of Scintimun® Granulocyte and labeled 99mTc-White Blood Cells in diagnosing infection/ inflammation by immunoscintigraphy in peripheral bone and joints with suspected osteomyelitis.
EUCTR2006-000514-21-CZCIS bio International130